BusinessXOMA Reports Third Quarter 2016 Achievements and Financial ResultsBy Nasdaq OMXNov 9, 2016, 2:00 PM UTC
BusinessXOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with Congenital HyperinsulinismBy Nasdaq OMXOct 19, 2016, 1:01 PM UTC
BusinessXOMA Provides Update from Ongoing Phase 2 XOMA 358 Clinical StudiesBy Nasdaq OMXSep 15, 2016, 11:26 PM UTC
BusinessChiasma Joins Patient Organizations Worldwide in Support of Rare Disease DayBy Nasdaq OMXFeb 29, 2016, 1:00 PM UTC
BusinessArQule Provides Proprietary Pipeline Update for AKT InhibitorsBy Nasdaq OMXJan 28, 2016, 12:30 PM UTC
BusinessAchillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology and Nomination of ACH-4471, a Novel Small Molecule Factor D Inhibitor, for Clinical DevelopmentBy Nasdaq OMXDec 5, 2015, 10:00 PM UTC
